Skip to content

Viridian Therapeutics

US · VRDN #2731 by market cap Listed 1970
29.96 -1.48 -4.71%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
  • Total institutional ownership fell 0.1 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
117.26% -0.14pp
Institutions
278 +5
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund69.20%
Hedge Fund32.95%
VC/PE Fund8.75%
Public Company2.97%
Private Company1.46%
Sovereign Wealth Fund1.32%
Government Pension Fund0.30%
Insurance Company0.28%

Top holders as of 2026-09-30

FMR 15.42% · 17.51M sh
BlackRock 8.22% · 9.33M sh
Bellevue Asset Management AG 5.93% · 6.73M sh
Paradigm Biocapital Advisors LP 5.92% · 6.72M sh
T. Rowe Price Group, Inc. 5.06% · 5.75M sh
Point72 Asset Management, L.P. 5.01% · 5.69M sh
Fairmount Funds Management LLC 4.48% · 5.09M sh
State Street Global Advisors 4.29% · 4.88M sh
Vanguard Capital Management, LLC 4.19% · 4.75M sh
Deep Track Capital, LP 3.16% · 3.59M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 38 buys · 11 sells

NameRoleStake
Radhika Tripuraneni Chief Medical Officer 0.04%
Stephen Mahoney Chief Executive Officer 0.03%
Thomas Beetham Chief Operating Officer 0.01%
Seth Harmon Chief Financial Officer 0.01%
Arlene Morris Independent Director --
Jeffrey Ajer Independent Director --
Tomas Kiselak Independent Chairperson of Board --
Christopher Cain Independent Director --
Jennifer Moses Independent Director --
Fairmount Funds Management LLC -- --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-08-18 Jennifer Tousignant Chief Legal Officer Open Market Disposition -4,212 $24.50
2026-08-18 Jennifer Tousignant Chief Legal Officer Derivative Exercise and Sale -10,000 $14.41–24.50
2026-08-13 Radhika Tripuraneni Chief Medical Officer Derivative Exercise and Retained +40,000 $13.21
2026-06-30 Arlene Morris Independent Director Other Derivative Acquisition +32,341 $18.48
2026-06-30 Jeffrey Ajer Independent Director Other Derivative Acquisition +32,341 $18.48
2026-06-30 Tomas Kiselak Independent Chairperson of Board Other Derivative Acquisition +32,341 $18.48
2026-06-30 Christopher Cain Independent Director Other Derivative Acquisition +32,341 $18.48
2026-06-30 Jennifer Moses Independent Director Other Derivative Acquisition +32,341 $18.48
2026-06-30 Sarah Gheuens Independent Director Other Derivative Acquisition +32,341 $18.48
2026-05-10 Fairmount Funds Management LLC -- Open Market Acquisition +1,176,470 $17.00
2026-03-03 Thomas Beetham Chief Operating Officer Intent to Sell (Form 144) -3,048 $30.19
2026-03-03 Stephen Mahoney Chief Executive Officer Intent to Sell (Form 144) -7,408 $30.19
2026-03-03 Seth Harmon Chief Financial Officer Intent to Sell (Form 144) -2,031 $30.19
2026-03-03 Jennifer Tousignant Chief Legal Officer Intent to Sell (Form 144) -1,675 $30.19
2026-03-02 Thomas Beetham Chief Operating Officer Sale to Issuer -3,048 $30.19
2026-03-02 Thomas Beetham Chief Operating Officer Derivative Exercise and Retained +9,409 --
2026-03-02 Stephen Mahoney Chief Executive Officer Sale to Issuer -7,408 $30.19
2026-03-02 Stephen Mahoney Chief Executive Officer Derivative Exercise and Retained +18,357 --
2026-03-02 Seth Harmon Chief Financial Officer Sale to Issuer -2,031 $30.19
2026-03-02 Seth Harmon Chief Financial Officer Derivative Exercise and Retained +6,267 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Viridian Therapeutics discussion 0 comments

Add a comment